Andrew Alexander Knox

Title: Andrew Alexander Knox: Innovator in Immunotherapy

Introduction

Andrew Alexander Knox is a prominent inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly in the development of T cell receptors that target specific tumor antigens. His work is crucial in advancing treatments for malignant diseases.

Latest Patents

One of Knox's notable patents is titled "T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex." This invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLMWITQC, derived from the cancer antigen NY-ESO-1. The TCRs may include mutations within the alpha and/or beta variable domains compared to a native NY-ESO-1 TCR. These TCRs are particularly suitable for use as novel immunotherapeutic agents in treating malignant diseases. Knox holds 1 patent in this area.

Career Highlights

Andrew Knox is associated with Immunocore Limited, a company that focuses on developing innovative immunotherapies. His work at Immunocore has positioned him as a key player in the field of cancer treatment, contributing to the advancement of therapeutic options for patients.

Collaborations

Knox collaborates with notable colleagues, including Fiona Chester and Jonathan Patrick Lowther. Their combined expertise enhances the research and development efforts at Immunocore Limited.

Conclusion

Andrew Alexander Knox is a significant figure in the field of immunotherapy, with a focus on T cell receptors that target tumor antigens. His contributions are paving the way for new treatment options in the fight against cancer.